Brand Name
Zemplar
Generic Name
Paricalcitol
View Brand Information FDA approval date: April 17, 1998
Classification: Vitamin D3 Analog
Form: Injection, Capsule
What is Zemplar (Paricalcitol)?
ZEMPLAR is a vitamin D analog indicated in adults and pediatric patients 10 years and older for the prevention and treatment of secondary hyperparathyroidism associated with: Chronic kidney disease Stages 3 and 4.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis
Summary: The purpose of this pilot study to examine the feasibility and acceptability of paricalcitol in adults with Chronic Pancreatitis (CP).
European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel Therapies
Summary: The hereditary type IV collagen disease Alport syndrome leads to kidney failure early in life. Currently there are no specific medications approved for treatment, however, several therapies have been evaluated preclinically and could improve outcome. For that reason, this non-interventional, observational study investigates, if medications (1) delay disease progression; (2) delay time to kidney fa...